Scientists bring hope to treat COVID-19 with the help of immune clue that will surely be beneficial for the complete elimination of coronavirus from the world.
Science Experts of the UK will start a trial for a treatment that they are seeing seems hopefully could be effective for COVID-19 patients especially with a critical illness.
After great study to determine about the coronavirus, it has been dug out the patients for COVID-19 with serious conditions have probably the less number of T-cells.
White blood cells, T-cells, the type of lymphocytes are the defensive cells that protect our immunity and prevent it from being destroyed; they especially work to encounter the prevailing disease known as COVID-19.
Scientists, in their trial, will use the proteinaceous drug, Interleukin 7 which is useful to induce the productivity of T-lymphocytes cells, and they will check out whether the trial is effective for the patients surviving with COVID-19.
Scientists from different research institutes have come up with authentic data when they examined 60 COVID-19 patients. They observed that the patients of this disease have a prominent decline in the count of T-cells.
Prof Adrian Hayday from Crick Institute was “surprised” to observe drastic changes in Immune cells.
T-cells are doing their best in order to make us get out of this disease but the virus is following its own strategy that seems to be eliminating all the assistance and support to halt the patient’s immunity from being reinstated.
One microlitre drop of blood of an adult normally contains 2,000 to 4,000 T lymphocytes. However, a COVID-19 patient has around 200 to 12,00 T-cells.
These findings would help make a way for the researchers to develop a potential test to examine the number of T lymphocytes that could be acting as a helper to offer early indications of the person who might develop more severity in his disease.
As well as, it also indicates the way for a specific treatment that would be meaningful to bump up the level of T lymphocytes in the blood.
Intensive care consultant at Guy’s and St Thomas’ Hospital, Manu Shankar-Hari made a statement that he observes about 70% of the COVID-19 patients in the intensive care unit lose the number of T-cells (400 to 800 T-cells per microlitre), that is way less than the normal adult contains.
Moreover, he said, as the patients get recovered from the disease caused by a coronavirus, they start producing a high amount of T-cells.
In the trial, Interleukin 7 will be given to severely ill patients with the largely low level of T lymphocytes, as it has been tested and proved to be successful in safely increasing the level of defensive cells.
Shankar-Hari is hoping that using this drug would definitely remove the disease from the body.
“Treatment like this is extremely encouraging for critical care physicians all over the UK, as no other treatment was there other than to give the patients intensive care against the disease,” he added.